LGI4 is a pivotal protein implicated in the development and function of the nervous system. Functioning primarily at the juncture of neural cells, LGI4 facilitates key processes that are essential for the proper communication between neurons. It is most notably recognized for its role in the formation of myelin, the insulating layer that enhances the speed and efficiency of electrical signal transmission along neural pathways. The expression of LGI4 is a tightly regulated process within the body, responding to a complex interplay of genetic and environmental signals. Aberrations in the expression of LGI4 have been linked to a spectrum of neural developmental disorders, highlighting the importance of understanding the mechanisms that govern its activity.
In the realm of biochemical research, a variety of chemical compounds have been identified that can potentially inhibit the expression of LGI4. These inhibitors operate through diverse mechanisms, each interacting with different molecular pathways to exert their influence on LGI4 expression levels. For instance, histone deacetylase inhibitors, such as Trichostatin A and Vorinostat, could potentially repress LGI4 expression by altering the conformation of chromatin, thereby restricting the access of transcriptional machinery to the LGI4 gene. Similarly, DNA methyltransferase inhibitors like 5-Azacytidine may lead to the hypomethylation of gene promoter regions, resulting in the suppression of LGI4 transcription. On another front, compounds that modulate signaling pathways, such as the PI3K inhibitor LY294002, could diminish LGI4 expression by interfering with downstream transcriptional processes. Moreover, inhibitors of receptor tyrosine kinases, exemplified by Sunitinib and Gefitinib, may also downregulate LGI4 by disrupting upstream signaling cascades that are integral for the initiation of LGI4 gene expression. Each of these chemicals, while not exclusively targeting LGI4, presents a unique approach to understanding the regulation of LGI4 at a molecular level. The study of these inhibitors provides valuable insight into the cellular mechanisms that control neural development and maintenance, expanding the breadth of knowledge in molecular neurobiology.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A may downregulate LGI4 expression by acetylating histones, thereby altering the accessibility of the gene's promoter region to transcriptional machinery. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By incorporating into DNA and RNA, 5-Azacytidine could decrease LGI4 expression through the hypomethylation of gene promoter regions, which would suppress transcription initiation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin might inhibit LGI4 synthesis by blocking mTOR activity, which is crucial for initiating cap-dependent translation, including the translation of mRNAs coding for LGI4. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV939 could reduce the expression of LGI4 by stabilizing axin and promoting beta-catenin degradation, subsequently decreasing Wnt signaling and its transcriptional activation of LGI4. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid could suppress LGI4 expression by binding to its receptors and altering the transcription of genes involved in the differentiation processes that include LGI4. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone might decrease LGI4 expression by antagonizing aldosterone receptors, leading to changes in mineralocorticoid-responsive gene transcription. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Hydroxyurea could reduce the expression of LGI4 by inhibiting DNA synthesis, leading to a general decrease in the transcriptional activity of various genes. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib may downregulate LGI4 expression by inhibiting multiple receptor tyrosine kinases and disrupting signal transduction pathways that promote LGI4 transcription. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib could inhibit LGI4 expression by blocking EGFR tyrosine kinase activity, which is often upstream of the signaling cascades controlling gene expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 might decrease LGI4 expression by inhibiting PI3K, leading to a reduction in AKT phosphorylation and a consequent fall in transcriptional activities that include LGI4. | ||||||